Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tumour infiltrating lymphocytes - Iovance Biotherapeutics/H Lee Moffitt Cancer Center and Research Institute

Next Previous
Drug Profile

Tumour infiltrating lymphocytes - Iovance Biotherapeutics/H Lee Moffitt Cancer Center and Research Institute

Alternative Names: TIL - Iovance Biotherapeutics/H. Lee Moffitt Cancer Center and Research Institute

Latest Information Update: 09 Sep 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Iovance Biotherapeutics
  • Developer Bristol-Myers Squibb; H. Lee Moffitt Cancer Center and Research Institute; Iovance Biotherapeutics; The V Foundation for Cancer Research
  • Class Antineoplastics; Immunotherapies; Tumour infiltrating lymphocyte therapies
  • Mechanism of Action Immunologic cytotoxicity; Lymphocyte replacements; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Adenocarcinoma; Colorectal cancer; Ovarian cancer
  • Phase I Non-small cell lung cancer
  • No development reported Malignant melanoma; Sarcoma

Most Recent Events

  • 22 Aug 2024 M.D. Anderson Cancer Center terminates phase II trial in Colorectal cancer (Second-line therapy or greater, Metastatic disease, Late-stage disease) in USA due to lack of efficacy (IV) (NCT03610490)
  • 22 Aug 2024 M.D. Anderson Cancer Center terminates phase II trial in Ovarian cancer (Second-line therapy or greater, Metastatic disease, Late-stage disease) in USA due to lack of efficacy (IV) (NCT03610490)
  • 22 Aug 2024 M.D. Anderson Cancer Center terminates phase II trial in Adenocarcinoma (Second-line therapy or greater, Metastatic disease, Late-stage disease) in USA due to lack of efficacy (IV) (NCT03610490)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top